Parliament and Government Summary — 15 May 2026

Parliamentary output was limited on Friday, so this summary focuses on two official updates rather than presenting a full sitting-day round-up. The main items were a medicines approval from the MHRA and the Government’s response to Lords committee work on AI, copyright and the creative industries.

At a glance

• Medicines regulation: the MHRA approved beremagene geperpavec, known as Vyjuvek, for the treatment of dystrophic epidermolysis bullosa.
• AI and copyright: the Government responded to a Lords Communications and Digital Committee report on the impact of artificial intelligence on copyright and the creative industries.

Government announcements

• The MHRA approved beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa, announced in a press release published on 15 May. The agency regulates the safety and effectiveness of medicines in the UK, and said it will keep Vyjuvek under close review after approval. [1]

Committees

• The Lords Communications and Digital Committee received the Government’s formal response to its report on AI, copyright and the creative industries, published on 15 May. The document answers a committee inquiry at Lords level on topics affecting creators and audiences, and shows how Ministers intend to address AI and copyright questions across the sector. [2]

Sources used

1. MHRA approves beremagene geperpavec (Vyjuvek) for the treatment of dystrophic epidermolysis bullosa — GOV.UK
2. Government response to the Committee’s report ‘AI, copyright and the creative industries’. 4th Report, Session 2024-26 — UK Parliament Committees

Licensing

Contains Parliamentary information licensed under the Open Parliament Licence v3.0.

Last updated

First published on 15 May 2026. No corrections at the time of publication.